Roth Capital Issues Optimistic Estimate for GANX Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Analysts at Roth Capital boosted their Q1 2025 earnings estimates for shares of Gain Therapeutics in a report issued on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan now expects that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.17). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($1.13) EPS.

A number of other equities analysts have also issued reports on GANX. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, March 17th. Roth Mkm restated a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Chardan Capital reiterated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research note on Friday, March 28th. Finally, Scotiabank assumed coverage on Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Gain Therapeutics has a consensus rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Trading Down 5.2 %

NASDAQ:GANX opened at $1.81 on Wednesday. The company has a market capitalization of $48.01 million, a PE ratio of -1.65 and a beta of 0.14. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.04. The stock’s 50 day moving average price is $2.20 and its 200 day moving average price is $2.07. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.07.

Institutional Investors Weigh In On Gain Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Sprott Inc. acquired a new stake in shares of Gain Therapeutics in the 4th quarter valued at approximately $30,000. Benedict Financial Advisors Inc. acquired a new stake in Gain Therapeutics in the fourth quarter valued at $35,000. Bridgeway Capital Management LLC purchased a new stake in shares of Gain Therapeutics during the 4th quarter worth $65,000. Northern Trust Corp grew its stake in shares of Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Gain Therapeutics in the 4th quarter valued at about $198,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.